JPWO2022101227A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022101227A5
JPWO2022101227A5 JP2023550714A JP2023550714A JPWO2022101227A5 JP WO2022101227 A5 JPWO2022101227 A5 JP WO2022101227A5 JP 2023550714 A JP2023550714 A JP 2023550714A JP 2023550714 A JP2023550714 A JP 2023550714A JP WO2022101227 A5 JPWO2022101227 A5 JP WO2022101227A5
Authority
JP
Japan
Prior art keywords
formula
pharma
parkinson
acceptable salt
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023550714A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023548429A5 (https=
JP2023548429A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/081162 external-priority patent/WO2022101227A1/en
Publication of JP2023548429A publication Critical patent/JP2023548429A/ja
Publication of JP2023548429A5 publication Critical patent/JP2023548429A5/ja
Publication of JPWO2022101227A5 publication Critical patent/JPWO2022101227A5/ja
Abandoned legal-status Critical Current

Links

JP2023550714A 2020-11-10 2021-11-09 パーキンソン病、特にｌ－ｄｏｐａ誘発性ジスキネジアのための医薬品に対する感作の予防または軽減における使用のための［２－（３－フルオロ－５－メタンスルホニルフェノキシ）エチル］（プロピル）アミン（メスドペタム） Abandoned JP2023548429A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20206645 2020-11-10
EP20206645.2 2020-11-10
PCT/EP2021/081162 WO2022101227A1 (en) 2020-11-10 2021-11-09 [2-(3-fluoro-5-methanesulfonylphenoxy)ethyl](propyl)amine (mesdopetam) for use in the prevention or reduction of sensitization to a pharmaceutical drug for parkinson's disease, in particular l-dopa induced dyskinesias

Publications (3)

Publication Number Publication Date
JP2023548429A JP2023548429A (ja) 2023-11-16
JP2023548429A5 JP2023548429A5 (https=) 2024-11-18
JPWO2022101227A5 true JPWO2022101227A5 (https=) 2024-11-18

Family

ID=73288427

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023550714A Abandoned JP2023548429A (ja) 2020-11-10 2021-11-09 パーキンソン病、特にｌ－ｄｏｐａ誘発性ジスキネジアのための医薬品に対する感作の予防または軽減における使用のための［２－（３－フルオロ－５－メタンスルホニルフェノキシ）エチル］（プロピル）アミン（メスドペタム）

Country Status (10)

Country Link
US (2) US20220168242A1 (https=)
EP (1) EP4243801A1 (https=)
JP (1) JP2023548429A (https=)
KR (1) KR20230106659A (https=)
CN (1) CN116685314A (https=)
AR (1) AR124036A1 (https=)
AU (1) AU2021378472A1 (https=)
CA (1) CA3198266A1 (https=)
TW (1) TW202233169A (https=)
WO (1) WO2022101227A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024062344A1 (en) * 2022-09-21 2024-03-28 Assia Chemical Industries Ltd. Solid state forms of mesdopetam and salts therof
GB202312055D0 (en) 2023-08-07 2023-09-20 Ipsen Biopharm Ltd Pharmaceutical compositions
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080036957A (ko) 2005-06-23 2008-04-29 아스트라제네카 아베 위장 질환 치료용 뉴로키닌 수용체 길항제로서의 신규한아제티딘 유도체
CN103347517B (zh) * 2010-08-11 2018-10-02 德雷克塞尔大学 治疗帕金森病中运动障碍的d3多巴胺受体激动剂
EP2699543B1 (en) 2011-04-19 2016-03-02 Integrative Research Laboratories Sweden AB Novel modulators of cortical dopaminergic- and nmda-receptor-mediated glutamatergic neurotransmission
EP2858649B1 (en) * 2012-06-11 2019-10-23 Psychogenics Inc. Treatment of motor and movement disorder side effects associated with parkinson's disease treatments
ES2869981T3 (es) * 2015-05-26 2021-10-26 Technophage Investig E Desenvolvimento Em Biotecnologia Sa Composiciones para su uso en el tratamiento de la enfermedad de parkinson y trastornos relacionados
WO2020110128A1 (en) * 2018-11-29 2020-06-04 Prilenia Neurotherapeutics Ltd. Combination of pridopidine and an additional therapeutic agent for treating drug induced dyskinesia
FI3976581T3 (fi) * 2019-05-24 2024-01-31 Irl 790 Ab [2-(3-fluori-5-metaani-sulfonyylifenoksi)etyyli](propyli)amiinin viinihapposuolat

Similar Documents

Publication Publication Date Title
JPS6143112A (ja) 精神性欲機能障害治療剤
CN107519159A (zh) 复方组合物
AU2012302106B2 (en) Use of organic compound for the treatment of noonan syndrome
WO2002078691A1 (en) Duloxetine for treatment of hot flashes
JP2022177119A5 (https=)
JP2004091473A (ja) 色素沈着改善治療薬
JPWO2022101227A5 (https=)
JP6454436B1 (ja) ペマフィブラートを含有する医薬
US20190224208A1 (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
CN1223338C (zh) 盐酸西替利嗪凝胶剂
US20040152733A1 (en) Duloxetine for treatment of hot flashes
JPH11269171A (ja) ５―（１，２―ジチオラン―３―イル―）吉草酸（α―リポ酸）またはその生理学的に許容しうる塩を有効成分とする脂肪代謝障害治療剤
CN101069688A (zh) 含有茶碱类药物和维生素k的药物组合物
JP3150642B2 (ja) 新規な抗痙攣性及び抗炎症性組成物並びにそれらの製造方法
WO2022183493A1 (zh) 一种多酚类化合物的应用
CN112691102A (zh) 黄芩素在防治帕金森病/帕金森综合征抑郁症状中的应用
CN103301115B (zh) 一种治疗癫痫的药物组合物
CN117159628A (zh) 茶褐素在制备防治铁过载相关疾病或降低机体铁蓄积产品中的应用
MX2008014577A (es) Combinaciones de erdosteina y beta-2 agonistas para el tratamiento de la enfermedad pulmonar obstructiva cronica.
CN107970248A (zh) 异甘草酸在制备治疗高血压药物中的用途
WO2026032374A1 (zh) 含联环的化合物用于治疗银屑病的用途
CN114288298A (zh) 一种复合吗啡制剂及其应用
CN121550210A (zh) 一种含二苯并呋喃结构的化合物在制备预防和/或治疗恶心呕吐的药物中的应用
CN110840869A (zh) 二甲双胍在子宫内膜异位症药物中的应用
JP2023512754A (ja) ＣａＳＲモジュレーターの医薬組成物ならびにその方法および使用